NCT02495922: Phase 3 - Elotuzumab in VRD Induction /Consolidation and Len maint in NDMM(GMMG-HD6)
- Completed
- Dec 13, 2015
- 1 min read
Updated: Sep 15, 2022
A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG-HD6)
German-speaking myeloma multicenter group
(GMMG)
Trial in patients with newly diagnosed myeloma to evaluate the effect of elotuzumab in induction and consolidation therapy with bortezomib/lenalidomide/dexamethasone and in lenalidomide maintenance treatment.
Sponsor
University of Heidelberg Medical Center
Information provided by (Responsible Party)
Prof. Dr. Hartmut Goldschmidt, University of Heidelberg Medical Center
German Study
ClinicalTrials.gov Identifier: NCT02495922
Official Title: A Randomized Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma
First Posted: July 13, 2015
Click here for details on ClinicalTrials.gov
Drug: elotuzumab
Drug: Lenalidomide
Drug: Bortezomib
Drug: Dexamethasone
Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma
BMC Cancer; 2019 May
731.AUTOLOGOUS TRANSPLANTATION: CLINICAL AND EPIDEMIOLOGICAL
NOVEMBER 5, 2021
Elotuzumab in Combination with Lenalidomide, Bortezomib, Dexamethasone and Autologous Transplantation for Newly-Diagnosed Multiple Myeloma: Results from the Randomized Phase III GMMG-HD6 Trial
Blood (2021) 138 (Supplement 1): 486.
Location
Germany
